Mitigating Effect of Estrogen in Alzheimer's Disease-Mimicking Cerebral Organoid

• Published in: Frontiers in neuroscience 2022-03, Vol.16, p.816174-816174
• Main Authors: Kim, Jennifer Yejean, Mo, Hyunkyung, Kim, Juryun, Kim, Jang Woon, Nam, Yoojun, Rim, Yeri Alice, Ju, Ji Hyeon
• Format: Article
• Language: English
• Subjects: Alzheimer’s disease; amyloid-beta; cerebral organoid; estrogen; induced pluripotent stem cells; Neuroscience
• ISSN: 1662-4548; 1662-453X; 1662-453X
• DOI: 10.3389/fnins.2022.816174

Alzheimer's disease (AD) is the most common condition in patients with dementia and affects a large population worldwide. The incidence of AD is expected to increase in future owing to the rapid expansion of the aged population globally. Researchers have shown that women are twice more likely to be affected by AD than men. This phenomenon has been attributed to the postmenopausal state, during which the level of estrogen declines significantly. Estrogen is known to alleviate neurotoxicity in the brain and protect neurons. While the effects of estrogen have been investigated in AD models, to our knowledge, they have not been investigated in a stem cell-based three-dimensional system. Here, we designed a new model for AD using induced pluripotent stem cells (iPSCs) in a three-dimensional, culture system. We used 5xFAD mice to confirm the potential of estrogen in alleviating the effects of AD pathogenesis. Next, we confirmed a similar trend in an AD model developed using iPSC-derived cerebral organoids, in which the key characteristics of AD were recapitulated. The findings emphasized the potential of estrogen as a treatment agent for AD and also showed the suitability of AD-recapitulating cerebral organoids as a reliable platform for disease modeling and drug screening.